PTJ
MPLT

Paul Tudor Jones’s MapLight Therapeutics MPLT Stock Holding History

Paul Tudor Jones’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-36,740
Closed -$747K – 4443
2026
Q1 		$747K Sell
36,740
-11,100
-23% -$199K ﹤0.01% 2567
2025
Q4 		$840K Buy
+47,840
New +$802K ﹤0.01% 2392

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Paul Tudor Jones's MPLT Position: Q2 2026 in Review

Paul Tudor Jones sold out of MapLight Therapeutics (MPLT) in Q2 2026, closing a stake of 36,740 shares — an estimated $747K sold.

Paul Tudor Jones first reported a position in MPLT in Q4 2025 and held it in 2 quarters. The position peaked at $840K in Q4 2025. 105 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Paul Tudor Jones reported no remaining MapLight Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 36,740 MapLight Therapeutics shares in Q2 2026, an estimated $747K.
  • Paul Tudor Jones first reported a position in MapLight Therapeutics in Q4 2025 and held it in 2 quarters.
  • Paul Tudor Jones's MapLight Therapeutics position peaked at $840K in Q4 2025.
  • 105 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.